Fulgent Genetics (FLGT) AI Stock Analysis

Fulgent Genetics

(BMV:FLGT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverage and strong liquidityExtremely low leverage and substantial liquidity give Fulgent flexibility to fund operations, acquisitions, product development, and therapeutic programs without heavy debt pressure. This financial cushion can help the company absorb execution setbacks while working to restore profitability.

Negative Factors

Persistent losses and cash burnSustained operating losses and renewed cash burn indicate that the current business is not yet self-funding. If negative cash generation continues, liquidity will gradually be consumed and management may have less capacity to invest in growth, acquisitions, or therapeutic development.

Fulgent Genetics (FLGT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 567.37M
Dividend Yield: ―
Average Volume (3M): 16
Price to Earnings (P/E): -7.3
Beta (1Y): 0.48
Revenue Growth: -2.67%
EPS Growth: -53.68%
Country: Mexico
Employees: 1,315
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Fulgent Genetics Business Overview & Revenue Model

Company Description

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers...

Fulgent Genetics Earnings Call Summary

Earnings Call Date:Jul 29, 2026(Q2-2026)|% Change Since:9.17%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call presents a mixed picture: meaningful operational and near-term financial headwinds driven by a complex revenue-cycle transition and loss of volume from a large customer led management to reduce full-year revenue guidance and report wider losses. Offsetting these challenges are strong cash reserves, successful integration of recent acquisitions, sequential margin improvement, continued share repurchases, product and AI advancements, and tangible progress in the therapeutic pipeline (FID-007 and FID-022). The issues are material to near-term results, but the company retains financial flexibility and long-term growth drivers.

Positive Updates

Therapeutic Pipeline Progress

FID-007 Phase II completed with encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma; end-of-Phase-II meeting with the FDA scheduled later this summer and Phase III registration trial targeted for H1 2027. FID-022 progressed to Phase I dose escalation with the first dose level completed and maximum tolerated dose expected later this year. Both candidates use Fulgent's proprietary CleanChemo platform (patented and fully owned).

Negative Updates

Revenue Cycle Transition Causing Lower Collection Rates

Transition to a new billing/revenue cycle management system (final phase) caused delays in billing, reduced collection rates and suppressed revenue recognition in Q2. Customizations remain incomplete and management cannot predict exact timing for recovery to historical collection rates.

Company Guidance

Fulgent revised full‑year 2026 guidance to $330–$340 million of revenue (down from prior $350M), implying ~2.3%–5.4% y/y growth, with segment targets of Precision Diagnostics $161–$166M, Anatomic Pathology $146–$150M, and BioPharma Services $23–$24M (Bako/StrataDX expected to add ~$53M in H2); they expect non‑GAAP gross margin in the mid‑30% range and non‑GAAP operating margin in the mid‑negative‑20% range, non‑GAAP EPS of a loss of $2.22–$2.35 per share based on ~28M diluted shares (down from ~29M), therapeutic development spend of ~$26M, capex of ~$12M, ending cash of about $610M (Q2 cash ~$551.5M), and no single customer to represent more than 10% of 2026 revenue.

Fulgent Genetics Risk Analysis

Fulgent Genetics disclosed 81 risk factors in its most recent earnings report. Fulgent Genetics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Fulgent Genetics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:FLGT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRA	67Neutral	$59.72B	-304.63	-11.73%	―	37.82%	28.02%
GH	55Neutral	$23.99B	-51.23	211.46%	―	42.74%	-4.60%
NEO	54Neutral	$2.25B	-70.42	-3.97%	―	11.08%	71.76%
MYGN	52Neutral	$607.38M	-5.32	-32.59%	―	-3.16%	72.02%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WGS	48Neutral	$2.06B	-18.97	-38.72%	―	25.42%	-10900.00%

* Healthcare Sector Average

Performance Comparison

MX:FLGT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:FLGT	Fulgent Genetics	376.21	-36.79	-8.91%
MYGN	Myriad Genetics	6.35	-1.83	-22.37%
NEO	NeoGenomics Inc.	17.38	7.60	77.71%
NTRA	Natera Inc.	414.30	216.07	109.00%
GH	Guardant Health	178.80	79.88	80.75%
WGS	Genedx Holdings Corp.	69.06	-69.24	-50.07%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Fulgent Genetics AI Stock Analysis